Dashboard

Gilead Sciences, Inc.

GILDNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$161B

Price$129.3152w $105.93 – $155.80

Conviction3/ 5

Revenue (TTM)$29.7B

Revenue growth YoY+3.5%

P/E (trailing)17.4

Gross margin79.4%

Operating margin38.6%

Net margin31.0%

52w price change+18.7%

Next earningsAug 4, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

Jul 16
Ownership changeSEC
Form 4 insider transaction filing reported for GILD.
Jul 16
Ownership changeSEC
Form 4 insider transaction filing by Gilead executive.
Jul 2
Ownership changeSEC
Form 4 insider ownership change filing for GILD.
Jun 16
Ownership changeSEC
SEC Form 4 insider transaction filing.
Jun 16
Ownership changeSEC
Form 4 filing reporting change in beneficial ownership by insider.
Jun 11
Ownership changeSEC
Form 4 insider transaction filing for GILD.
Jun 11
Ownership changeSEC
Form 4 insider transaction filing.
Jun 11
Ownership changeSEC
SEC Form 4 filing for change in insider ownership.
Jun 11
Ownership changeSEC
SEC Form 4 insider beneficial ownership change filing.
Jun 11
Ownership changeSEC
SEC Form 4 filing for insider ownership change at Gilead Sciences.
Jun 2
OtherClinicalTrials.gov
Phase 3 trial NCT05568095 (domvanalimab + zimberelimab + chemo, upper GI cancer) sponsored by Arcus Biosciences updated to ACTIVE_NOT_RECRUITING status.
Jun 2
OtherClinicalTrials.gov
Phase 2 trial NCT05329766 (upper GI malignancies) sponsored by Arcus Biosciences updated to ACTIVE_NOT_RECRUITING status on 2026-06-02.
Jun 2
Ownership changeSEC
Form 4 filing reporting change in insider beneficial ownership.
Jun 1
OtherClinicalTrials.gov
Arcus Biosciences Phase 2 trial NCT04736173 (zimberelimab + domvanalimab, lung cancer) status updated to ACTIVE_NOT_RECRUITING.
Jun 1
Trial initiationClinicalTrials.gov
Gilead phase 2 trial NCT05633667 (lung cancer combos) status updated to ACTIVE_NOT_RECRUITING
Jun 1
Trial readoutClinicalTrials.gov
Gilead phase 2 lung cancer immunotherapy trial (NCT05676931) status updated to ACTIVE_NOT_RECRUITING
May 27
OtherSEC
SEC Form 4 filing reporting change in beneficial ownership of securities
May 27
OtherClinicalTrials.gov
UNICANCER trial NCT03275311 status updated to RECRUITING
May 20
DealSEC
8-K filing (items 1.01,2.03,8.01,9.01) on material agreement and financial obligation.
May 18
OtherSEC
SEC Form 4 insider ownership filing for GILD.

Not financial advice — research and opinion only. Disclosures